



HARMONIZED SYSTEM
COMMITTEE
-
23rd Session
-

NC0078E1
(+Annex)
O. Eng.

Brussels, 19 April 1999.

CLASSIFICATION OF NEW INN PRODUCTS (WHO LIST 80)

(Item V.5 on Agenda)

Reference documents :

42.825 (SSC/14)
42.850 Annex A/3 (SSC/14 - Report)

I. BACKGROUND

1. The Scientific Sub-Committee, at its 14th Session (February 1999), discussed the classification of certain INN products and pharmaceutical intermediates (see Annex A/3 to Doc. 42.850, Report – SSC/14).
2. Concerning the classification of new INN products (WHO List 80), the Sub-Committee decided to follow the same review procedure that it had applied to WHO List 78, since the working document (Doc. 42.825) had only been published immediately prior to the meeting. Therefore, delegates to the Scientific Sub-Committee were requested to submit their comments on the proposed classifications mentioned in the Annex to Doc. 42.825 to the Secretariat. The agreed classifications, after receiving the approval of the Chairman of Scientific Sub-Committee, would be submitted to the 23rd Session of the Harmonized System Committee.

II. SECRETARIAT COMMENTS

3. As of 24 March 1999, the Secretariat has received comments from Canada, Japan, Switzerland and the United Kingdom. Taking into account the comments received, the Secretariat has prepared a list of INNs on which there appears to be a consensus as to classification. This list is identified in the Annex to this document as “Agreed classification” in the Remarks column. The classifications considered to be agreed by delegates to the Scientific Sub-Committee and the corresponding INNs (49 cases) are indicated in **bold** type. The Annex also incorporates the list of products on which there were different views as to classification (27 cases). The proposed classifications in these cases have been placed in square brackets.

File No. 2549

4. The Secretariat forwarded the proposed classifications to the Chairman of the Scientific Sub-Committee for approval. On 1 April 1999, the Secretariat received a reply from the Chairman of the Scientific Sub-Committee, conveying his approval of the agreed classifications indicated in **bold** type in the Annex.
5. Based on the comments received from administrations and the Chairman of the Scientific Sub-Committee, the Committee is invited to approve the proposed classifications of these 49 INN products.
6. The classification of the remaining INN products (27 cases for which the proposed classification have been placed in square brackets in the Annex) will be submitted to the next (15th) Session of the Scientific Sub-Committee in January 2000.

III. CONCLUSION

7. The Committee is invited to approve the classifications of 49 INN products indicated in **bold** type in the Annex.

x

x x

INN LIST 80

<u>INN</u>	<u>Proposed HS code</u>	<u>Remarks</u>
Abaperidone	2934.90	Agreed classification
Alitretinoin	[2916.20] [2936.21]	
Anecortave	[2915.39] [2937.99]	
Artemotil	2932.99	Agreed classification
Arzoxifene	2934.90	Agreed classification
Atorolimumab	3002.10	Agreed classification
Avasimibe	[2929.90] [2935.00]	
Bexarotene	2916.39	Agreed classification
Carabersat	2932.99	Agreed classification
Caspofungin	[2933.90] [2941.90]	
Celecoxib	2935.00	Agreed classification
Corifollitropin alfa	[2934.40] [2937.99]	
Darbufelone	[2934.10] [2934.90]	
Depreotide	[2933.90] [2934.90]	
Deracoxib	[2935.00] [2937.99]	
Desloratadine	2933.39	Agreed classification
Desmoteplase	[3002.10] [3507.90]	
Dexbudesonide	[2914.40] [2932.99]	
Ecopipam	2933.90	Agreed classification
Emtricitabine	2934.90	Agreed classification
Enrasentan	2932.99	Agreed classification
Eplivanserin	2928.00	Agreed classification
Ethylcellulose	3912.39	Agreed classification
Etilevodopa	2922.50	Agreed classification
Exisulind	2930.90	Agreed classification
Fanapanel	2934.90	Agreed classification
Galarubicin	2941.90	Agreed classification
Gantofiban	2934.90	Agreed classification
Gimeracil	2933.39	Agreed classification
Hemoglobin glutamer	[3002.10] [3913.90]	
Hyetellose	3912.39	Agreed classification
Hymetellose	3912.39	Agreed classification
Hyprolose	3912.39	Agreed classification
Insulin detemir	[2934.90] [2937.99]	

Itavastatin	[2933.40] [2933.90]	
Leridistim	[2934.90] [29.37] [3002.10]	
Letepirim	2933.59	Agreed classification
Lopinavir	2933.59	Agreed classification
Lusupultide	[2924.29] [2933.29] [2933.90]	
Maribavir	2934.90	Agreed classification
Minopafant	2933.39	Agreed classification
Minretumomab	3002.10	Agreed classification
Mivotilate	2934.10	Agreed classification
Nesiritide	[2924.29] [2934.90] [2933.90] [3002.10]	
Olmesartan	[2933.29] [2934.90]	
Oseltamivir	2924.29	Agreed classification
Oteracil	2933.69	Agreed classification
Parecoxib	2935.00	Agreed classification
Pegacaristim	[2934.90] [2937.10] [2937.99] [3913.90]	
Pegnartograstim	[29.34] [3002.10] [3913.90]	
Ponazuril	2933.69	Agreed classification
Rofecoxib	2932.29	Agreed classification
Sarizotan	2934.90	Agreed classification
Satraplatin	[2843.90] [2942.00]	
Semparatide	[2924.10] [2933.29]	
Simeticone	[2931.00] [3003.90] [3824.90] [3910.00]	
Sitamaquine	2933.40	Agreed classification
Solimastat	2933.39	Agreed classification
Sonepiprazole	2935.00	Agreed classification
Tabimorelin	[2924.29] [2937.99]	
Tafenoquine	2933.40	Agreed classification
Talampanel	2934.90	Agreed classification
Telithromycin	2941.90	Agreed classification

Tenatoprazole	2933.39	Agreed classification
Teriflunomide	2926.90	Agreed classification
Timcodar	2933.39	Agreed classification
Tipranavir	2935.00	Agreed classification
Tonabersat	2932.99	Agreed classification
Tositumomab	[3002.10]	
Travoprost	[2918.90] [29.37]	
Upidosin	2934.90	Agreed classification
Valdecoxib	2935.00	Agreed classification
Vangatalcite	[2838.99] [2842.90]	
Vepalimomab	[3002.10]	
Vilazodone	2934.90	Agreed classification
Volpristin	2934.90	Agreed classification